SCHEMBL623349

SCHEMBL623349

Cc1ccc(C(=O)O)c(CO)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 1/20 0.52
BRD4 O60885 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 2/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 1/20 0.42
HTT P42858 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
MCL1 Q07820 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
MAOB P27338 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1549076 0.86 CSNK2A1 (0.53) CSNK2A1BRD4MEN1KMT2AALDH1A1
SCHEMBL29140046 0.85 CSNK2A1 (0.48) CSNK2A1BRD4MEN1KMT2AALDH1A1
SCHEMBL9912234 0.84 CSNK2A1 (0.57) CSNK2A1MEN1KMT2AALDH1A1POLB
SCHEMBL7774557 0.82 CSNK2A1 (0.50) CSNK2A1MEN1KMT2AALDH1A1KDM4E
SCHEMBL20943211 0.82 CSNK2A1 (0.50) CSNK2A1BRD4MEN1KMT2AALDH1A1
SCHEMBL18280409 0.82 CSNK2A1 (0.50) CSNK2A1BRD4MEN1KMT2AALDH1A1
SCHEMBL4638489 0.82 PARP1 (0.46) CSNK2A1MEN1KMT2AALDH1A1KDM4E
SCHEMBL2336414 0.82 SRC (0.54) CSNK2A1MEN1KMT2AALDH1A1KDM4E
SCHEMBL30388279 0.82 CSNK2A1 (0.50) CSNK2A1BRD4MEN1KMT2AALDH1A1
SCHEMBL15462885 0.82 CSNK2A1 (0.50) CSNK2A1BRD4MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS INC (US) 2023-05-04 US disclosed
EP-1890992-B1 AN ENRICHMENT PROCESS USING COMPOUNDS USEFUL IN A POLYESTER PROCESS GRUPO PETROTEMEX SA DE CV (MX) 2019-10-23 EP disclosed
EP-1888498-B1 A PROCESS TO PRODUCE AN ENRICHMENT FEED GRUPO PETROTEMEX SA DE CV (MX) 2019-06-26 EP disclosed
EP-1888497-B1 A PROCESS TO PRODUCE AN ENRICHED COMPOSITION THROUGH THE USE OF A CATALYST REMOVAL ZONE AND AN ENRICHMENT ZONE GRUPO PETROTEMEX SA DE CV (MX) 2019-04-17 EP disclosed
EP-2066612-B1 A PROCESS TO PRODUCE AN ENRICHMENT FEED GRUPO PETROTEMEX SA DE CV (MX) 2018-08-01 EP disclosed
US-10029973-B2 Optimized liquid-phase oxidation GROPO PETROTEMEX, S.A. DE C.V. (MX) 2018-07-24 US disclosed
US-20180072648-A1 OPTIMIZED LIQUID-PHASE OXIDATION GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2018-03-15 US disclosed
EP-2316566-B1 Bubble column reactor for gas-liquid exchange reactions GRUPO PETROTEMEX SA DE CV (MX) 2017-11-22 EP disclosed
EP-1791800-B1 OPTIMIZED LIQUID-PHASE OXIDATION GRUPO PETROTEMEX SA DE CV (MX) 2017-11-01 EP disclosed
EP-1881953-B1 A PROCESS TO PRODUCE AN ENRICHED CARBOXYLIC ACID COMPOSITION GRUPO PETROTEMEX SA DE CV (MX) 2017-10-25 EP disclosed
US-20060047155-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047151-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047149-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047157-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047154-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047142-A1 Optimized liquid-phase oxidation GRUPO PETROTEMEX, S.A. DE C.V. (MX) 2006-03-02 US disclosed
US-20060047161-A1 Optimized liquid-phase oxidation ALPEK POLYESTER, S.A. DE C.V. (MX) 2006-03-02 US disclosed
EP-0081611-B1 PROCESS FOR ELECTROCHEMICAL REDUCTION OF TEREPHTHALIC ACID AMOCO CORPORATION (US) 1985-10-09 EP disclosed
EP-0081611-A1 Process for electrochemical reduction of terephthalic acid AMOCO CORPORATION (US) 1983-06-22 EP disclosed
US-4381229-A Process for electrochemical reduction of terephthalic acid STANDARD OIL COMPANY (INDIANA) (US) 1983-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133817-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC CSNK2A1 1833/4885BRD4 1705/4885MEN1 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.